Skip to main content

CHS Cancer Clinical Trials

roswell park chsli logo


The Future of Cancer Therapy

CHS is strengthening its commitment to providing outstanding cancer care for Long Islanders by becoming a member of Roswell Park Care Network. Based in upstate New York, Roswell Park has long enjoyed a sterling reputation as one of the nation's premier cancer centers.

Now it is partnering with physicians, hospitals and supportive care teams across the state to create an expansive community-based care network dedicated to easing the burden of cancer. This network provides increased access to clinical trials—some of which are only available at Roswell Park.

Through its affiliation with Roswell Park, CHS has the opportunity to provide cancer patients with some of the newest and most innovative treatments available only through clinical trials.

Call 844-86-CANCER (844-862-2623) or submit a form for more information.

The Future of Cancer Care at Roswell Park (Video courtesy of Roswell Park Comprehensive Care Center)

Learn more about Roswell Park (Video courtesy of Roswell Park Comprehensive Care Center)

Find a CHS Cancer Institute near you

Why Clinical Trials?

Scientist with mircroscope

A clinical trial is a type of clinical research study that tests the safety and effectiveness of new medical approaches. Some clinical trials test a drug, a medical device or a new way of doing surgery. Other trials test new ways to prevent disease, diagnose cancer or improve quality of life. Clinical trials play an essential role in the fight against cancer. They are the only scientific way to prove whether a new treatment works better than the current standard of care. (Source: Roswell Park)

Learn more to help you decide about participation in a clinical trial

What You Need to Know About Clinical Trials

Current Open Clinical Trials

Breast Cancer

  • Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  • A Randomized Phase III Double Blinded Placebo Controlled Trial of Asprin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
  • A phase lll Double-blind randomized study assessing the efficacy of capivasertib + paclitaxel versus placebo + paclitaxel as first-line treatment for patients with histologically confirmed locally advanced or metastatic triple-negative breast cancer (TNBC)

Chronic Lymphocytic Leukemia

  • Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia

Colon Cancer

  • Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch

Metastatic Disease

  • ASTEROID- Assessing Single-Fraction SBRT versus Standard Palliative Radiation in Patients with Metastatic Disease

Multiple Myeloma

What is multiple myeloma?

Watch: Signs and Symptoms of Myeloma (Courtesy of Roswell Park Comprehensive Care Center)

  • Phase II Study of Targeting CD28 in Multiple Myeloma with Abatacept to Overcome Resistance to Chemotherapy
    • Principal Investigator: Dr. Dilip Patel
    • Summary: This Phase II trial studies how well abatacept, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that is resistant to chemotherapy. Abatacept may block certain proteins that are present on multiple myeloma cells that have been shown to protect against chemotherapy. Drugs used in chemotherapy, such as ixazomib citrate and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abatacept, ixazomib citrate, and dexamethasone may work better at treating patients with multiple myeloma resistant to chemotherapy.
    • Read more about the study
  • (LocoMMotion Study): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment


  • Cadence Registry Sanofi CADENCE Registry - Cold Agglutinin Disease Real World Evidence Registry 
    • Principal Investigator: Dr. George Zervos
  • Advanced Cardiac Imaging in Detection of Cardiotoxicity of Cancer Chemotherapy
    • Principal Investigator: Dr. Nathaniel Reichek
  • St. Francis Hospital Cardio-Oncology Registry 
    • Principal Investigator: Dr. Haoyi Zheng
  • The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
    • Principal Investigator: Dr. Dilip Patel

Contact Us